VIR News | Roxom Stocks

1 BTC

- USD

Loading market data...

Mkt Cap

$1.69B

Volume

1.42M

Next Earnings

November 4th

Mkt Cap

$1.69B

Volume

1.42M

Next Earnings

November 4th

Chart Financials Earnings News About Insider Filings

Can Gilead's Deal With VIR Boost Its Oncology Pipeline and Growth?Gilead Sciences entered a collaboration with Vir Biotechnology to develop three novel T-cell engagers targeting solid tumors. Vir will receive $90 million upfront plus up to $1.74 billion in milestone payments. The deal reflects Gilead's strategy to diversify beyond HIV into oncology, though near-term profitability faces pressure from deal costs and competition from rivals like AstraZeneca and Bristol Myers in cancer therapies.Zacks Investment Research · Oct 15, 2026

Why a Biotech Fund Opened a New $6 Million Position in Vir Amid a 99% Stock RallySuperstring Capital Management established a new $5.82 million position in Vir Biotechnology by acquiring 730,548 shares in Q1 2026. The investment appears to be a bet on upcoming clinical catalysts rather than current financials, with Vir expecting Phase 3 hepatitis delta data in Q4 2026 and pivotal Phase 3 oncology trials in 2027. Despite being unprofitable, the company has a strong balance sheet with $809.3 million in cash and runway into late 2028.The Motley Fool · May 23, 2026

"Cold" Solid Tumors Become the Proving Ground for a New Generation of Engager and Immune-Priming TherapiesA new generation of immuno-oncology therapies targeting historically immunotherapy-resistant solid tumors like prostate and pancreatic cancer is advancing rapidly through clinical trials in 2026. Four distinct mechanistic approaches—including NK cell engagers, oncolytic virus immune-primers, and tumor microenvironment-conditional antibodies—are being developed by multiple biotech companies, with over $1.7 billion in dealmaking activity. GT Biopharma's GTB-5550 NK cell engager and Vir Biotechnology's VIR-5500 PSMA-targeted T-cell engager represent leading programs in this emerging therapeutic landscape.GlobeNewswire Inc. · May 14, 2026

Vir Biotechnology (VIR) CEO Sells 73,000 Shares for $664,000Vir Biotechnology CEO Marianne De Backer sold 72,559 shares worth $664,350 on April 6, 2026, representing 6.76% of her holdings. The sale aligns with her historical selling patterns and appears to be income supplementation rather than a loss of confidence. The company has shown positive momentum with encouraging clinical trial results for VIR-5500 and a significant partnership deal with Astellas Pharma worth $315 million.The Motley Fool · Apr 12, 2026

Stock Market Today: S&P 500 Futures Slip As Dow, Nasdaq 100 Gain Following Trump's Tariff Threat — Whirlpool, Uber, HP In Focus (UPDATED)U.S. stock futures rose on Tuesday following Monday's sell-off triggered by AI-related economic concerns and a viral 'Global Intelligence Crisis' report. Market sentiment remains cautious amid Trump's tariff threats and geopolitical tensions. Key movers include Keysight Technologies surging 16% on strong earnings, Vir Biotechnology jumping 63% on revenue beat, and Whirlpool plunging 7.46% after announcing an $800 million capital raise.Benzinga · Feb 24, 2026

Is Alnylam Pharmaceuticals a Millionaire Maker?Alnylam Pharmaceuticals, a biotech company focused on RNA interference (RNAi) therapies, has shown significant growth since its 2004 IPO. The company has multiple approved drugs for rare diseases and a promising pipeline of potential treatments across various medical conditions.The Motley Fool · Dec 7, 2025

Vir (VIR) Q2 Revenue Drops 61%Vir Biotechnology reported a Q2 2025 net loss of $0.80 per share, with revenues of $1.2 million. The company advanced its clinical pipeline in hepatitis delta and oncology, maintaining $892.1 million in cash reserves while continuing to invest in research and development.The Motley Fool · Aug 7, 2025

Biotech Stock Roundup: GSK's Litigation Update, BIIB's Drug Approval & Other UpdatesGSK and Biogen (BIIB) are in the spotlight following litigation updates and drug approval, respectively.Zacks Investment Research · Jun 6, 2024

Vir Biotechnology (VIR) Up on Positive Data From HDV StudyVir Biotechnology (VIR) rises on upbeat data from its phase II study evaluating tobevibart and elebsiran for the treatment of people living with chronic hepatitis delta.Zacks Investment Research · Jun 6, 2024

Evaluating Vir Biotechnology: Insights From 5 Financial AnalystsAcross the recent three months, 5 analysts have shared their insights on Vir Biotechnology (NASDAQ:VIR), expressing a variety of opinions spanning from bullish to bearish. The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 4 0 1 0 0 Last 30D 1 0 0 0 0 1M Ago 2 0 1 0 0 2M Ago 0 0 0 0 0 3M Ago 1 0 0 0 0 Analysts have set 12-month price targets for Vir Biotechnology, revealing an average target of $71.4, a high estimate of $110.00, and a low estimate of $12.00. Witnessing a positive shift, the current average has risen by 614.0% from the previous average price target of $10.00. Deciphering Analyst Ratings: An In-Depth Analysis The analysis of recent analyst actions sheds light on the perception of Vir Biotechnology by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets. Analyst Analyst Firm Action Taken Rating Current Price Target Prior Price Target Patrick Trucchio HC Wainwright & Co. Maintains Buy $110.00 - Patrick Trucchio HC Wainwright & Co. Maintains Buy $110.00 - Eric Joseph JP Morgan Raises Neutral $12.00 $10.00 Joseph Stringer Needham Maintains Buy $15.00 - Patrick Trucchio HC Wainwright & Co. Maintains Buy $110.00 - Key Insights: Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to ...Full story available on Benzinga.comBenzinga · May 24, 2024

VIRVir Biotechnology, Inc. Common Stock

VIR

Pay with—

Start Trading

Available Balance0.00

Your PositionYou don't own any VIR yet.

Related Tickers

Earnings

Mkt Cap

$1.69B

Volume

1.42M

Next Earnings

November 4th